__

PWRM, Power 3 Medical Products Inc. (PWRM.OB)

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 & is based in The Woodlands, Texas.

To Power3’s Shareholders,

As CEO of your company, I would like to take this opportunity to report to you, our shareholders, on the immense progress we have made over the past several months.

This is a very exciting time for Power3 Medical Products. We have achieved many milestones and have identified several others that we are on target to achieve throughout 2008. Power3 has remained focused on breast cancer and neurodegenerative diseases (Alzheimer’s, Parkinson’s and ALS) and is working in collaboration with world-renowned institutions and industry leaders to find solutions for early and more accurate detection of these devastating conditions. We have a strong team supporting the company including: Dr. Ira L. Goldknopf, Director of Proteomics; Dr. Essam Sheta, Director of Biochemistry; and a world class Scientific Advisory Board.

In our journey transitioning from an R & D company to the commercialization of our technology and products, we have already completed a number of validation studies with several more currently underway. During the past year we received our Clinical Laboratory Improvement Amendment (CLIA), a certification that ensures that we meet quality laboratory testing guidelines. This month we received CLIA compliance recertification following a CLIA regulatory inspection. This is a great achievement for Power3: with the CLIA certification, our laboratory is approved for testing to ensure accuracy, reliability, and timeliness of patient test results regardless of where the test was performed. Our branding is also a very important step in moving towards commercialization of the BC-SeraPro and NuroPro tests, and our trademarks for each of our early detection blood serum diagnostic tests were approved.

In August 2007 we announced the conclusion of a sixty patient blinded validation study of our BC-SeraPro(TM) early detection blood serum breast cancer test. We used twenty-two biomarkers to obtain the results from this study, which yielded 97% sensitivity and 93% specificity using decision tree analysis, and 80% sensitivity and 87% specificity using Linear Discriminant Analysis. These results were a major step forward in commercializing the BC-SeraPro test and are essential to moving forward with our strategy of providing an accurate and inexpensive blood serum diagnostic test for breast cancer. In addition to the completion of this validation study, additional validation studies are ongoing in the United States and international locations that will provide additional patient samples to Power3.

Power3 accomplished another significant milestone in October 2007 when we signed a distribution agreement to launch our BC-SeraPro blood serum diagnostic test in twelve Middle Eastern countries with Financial Advisory House’s Medical Equipment Suppliers division (FAH), a Bahrain-based medical instrument distribution company. The agreement allows for the distribution of the BC-SeraPro test in: Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia, Oman, Qatar, Syria, the United Arab Emirates, and Yemen. We plan to launch the BC-SeraPro test in the Middle East upon completion of a Middle East Validation Study.

Concerning this initiative, I recently returned from a trip to the Middle East where I met with government officials, health, and medical representatives in several different countries. With the high rate of breast cancer in the Middle East, there is an overwhelming need and demand for alternative and accurate early detection methods. The governments of these countries are eager to provide to their citizens a low cost alternative early detection method that will save lives and ultimately lower health care spending. We feel the Middle East is an ideal place for the launch of our BC-SeraPro test as evidenced by the United Arab Emirates recent decision to grant free breast cancer screening for all women in the UAE over the age of thirty-five.

In addition to our progress in clinical validation studies of our BC-SeraPro test, Power3 is also advancing in its clinical validation studies for Parkinson’s and Alzheimer’s disease. We recently began a three hundred patient clinical validation study of our NuroPro diagnostic test for Alzheimer’s and Parkinson’s disease. This clinical validation study is a blinded study led by Dr. Marwan Sabbagh as the Principle Investigator at the Sun Health Research Institute. Additionally, we are currently evaluating our NuroPro test in a one hundred fifty patient validation study with the University of Thessaly Medical School in Greece with Dr. Katerina Markopoulou as the principal investigator. Throughout our clinical validation studies, we continue to add to our existing database of patient samples, which now number over 2,200.

Our scientific team is responsible for the identification and collection of the 543 biomarkers we have successfully identified. The patent protection of our discoveries and the processes by which we use these protein biomarkers in our blood serum diagnostic tests is very valuable to us. Since January 2007 we have filed six new patents, we currently have eighteen patents.

In alignment with our scientific achievements, Power3 has recently published several noteworthy scientific papers. Dr. Goldknopf had an invited editorial published in Expert Review of Proteomics, providing further recognition of Power3’s leadership position in the proteomics field. Dr. Essam Sheta, Director of Biochemistry and Dr. Goldknopf, collaborated with Dr. Wael El-Rifai, Professor of Surgery, Medicine and Cancer Biology and Director of Surgical Oncology Research at Vanderbilt University Medical Center, Nashville, TN, to publish the discovery of protein biomarkers for esophageal malignancies in the International Journal of Cancer. Another noteworthy accomplishment for Power3 came with the publication of a whitepaper written by Dr. Hollingsworth titled “The Rationale for a Blood Test to Detect Early Breast Cancer.” In addition, Power3 was invited to deliver a poster presentation at the prestigious San Antonio Breast Cancer Symposium, a division of the Cancer Therapy & Research Center in December 2007. It was a great honor and achievement to be invited to present at the symposium, which aims to provide state-of-the-art information on breast cancer research.

It is our primary priority to remain dedicated to our work of developing early detection blood serum diagnostic tests. Over the past year we have been recognized for our work in a number of media pieces. Among the coverage Power3 has received, the company was highlighted in Popular Science, in December 2007, and Women’s Day Magazine in January 2008. In April 2008, Power3 was highlighted in The Drudge Report, The Daily Mail, Chemical & Industry Magazine, Genome Technology and BBC News. Additionally, Power3 was featured on Fox26 News in Houston in January 2008, ISTOE (Brazil) and iHNed (Czech Republic) in April 2008. I also recently had the pleasure of contributing articles to two magazines, IVD Technology and Pharmaceutical Formulation & Quality. These media pieces have continued to bring attention to our story and have gone on to reach the international market.

The company continues to seek synergistic strategic partners to license and develop its growing portfolio of protein biomarkers and tests. We are currently working on revising our agreement with Neogenomics.

Although at times the road to success may seem a bit bumpy, we are dedicated to our goal of developing and commercializing blood serum diagnostic tests for the early detection of disease. We believe we have created truly unique tests that are different from anything currently offered on the market. Our method of testing and ability to duplicate results differentiates us from any other company operating in our field.

I am confident that Power3 is on the path to successful commercialization of our blood serum diagnostic tests for the early detection of disease. I appreciate the support and loyalty of our shareholders and I remain dedicated to taking necessary steps in building and maintaining shareholder value. I am excited about our potential for great progress in the coming months and look forward to communicating all of Power3’s developments to the investment community and the general public.

Sincerely,

Helen R. Park, M.S.

Appointed Interim CEO

To learn more about PWRM visit: http://www.Power3Medical.com

***************************

GNBT, Generex Biotechnology Corp. (NASDAQ:GNBT)

GNBT, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. GNBT develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. GNBT’s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. GNBT’s under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. GNBT markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum. GNBT was founded in 1983 & is based in Toronto, Canada.

GNBT announced recently that it has named Craig Eagle, M.D. to its scientific advisory board. Dr. Eagle brings a wealth of oncology experience to help GNBT’s wholly-owned subsidiary, Antigen Express, Inc., dba “Generex Oncology”, further its synthetic cancer and influenza vaccine development efforts. Dr. Eagle currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc.

To learn more about GNBT visit: http://www.generex.com

***************************

HEB, Hemispherx Biopharma, Inc. (AMEX:HEB)

HEB, a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. HEB’s products include Ampligen, an experimental drug that is under clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, Hepatitis B, human immunodeficiency virus, renal cell carcinoma, and malignant melanoma; and Alferon N Injection for the treatment of genital warts. HEB’s products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of chronic viral and immunological disorders. HEB has a strategic alliance with Accredo to develop certain marketing and distribution capacities for Ampligen in the United States. HEB. was founded in 1990 & is headquartered in Philadelphia, Pennsylvania.

HEB recently announced that its six-year litigation battle with the South African investment conglomerate JCI Ltd., traded on the Johannesburg Stock Exchange, ended in victory August 11, 2010, with the entry of a $188 million judgment in HEB’s favor and against Johannesburg Consolidated Investments (JCI) and former JCI officers R.B. Kebble and H.C. Buitendag. Kebble and Buitendag used JCI Ltd. to pull off what South African authorities have called the largest financial fraud in that country’s history, engaging in numerous acts of securities fraud. As stated in HEB’s complaint, this included the illegal attempt to take over and pillage HEB.

To learn more about HEB visit: http://www.hemispherx.net

__

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)